Cue Biopharma, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
CUE$20.14+7.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31,2026 | December 31,2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $16,379 | $27,136 |
| Accounts receivable | 5,351 | 5,546 |
| Deposits, current portion | 1,062 | 1,093 |
| Prepaid expenses and other current assets | 1,701 | 1,309 |
| Foreign withholding tax receivable | 1,899 | 1,899 |
| Total current assets | 26,392 | 36,983 |
| Property and equipment, net | 288 | 241 |
| Operating lease right-of-use asset | 3,318 | 4,074 |
| Deposits | 635 | 666 |
| Restricted cash | 154 | 154 |
| Other long-term assets | 90 | 94 |
| Total assets | $30,877 | $42,212 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $3,327 | $3,948 |
| Accrued expenses | 1,499 | 1,611 |
| Research and development contract liability, current portion | — | 5,335 |
| Operating lease liabilities, current | 1,562 | 1,911 |
| Other current payable | 1,003 | 689 |
| Total current liabilities | 7,391 | 13,494 |
| Operating lease liabilities, non-current | 1,878 | 2,286 |
| Total liabilities | $9,269 | $15,780 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 300,000,000 shares authorized; 3,255,359 and 3,220,707 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 3 | 3 |
| Additional paid in capital | 395,249 | 394,895 |
| Accumulated deficit | (373,644) | (368,466) |
| Total stockholders’ equity | 21,608 | 26,432 |
| Total liabilities and stockholders’ equity | $30,877 | $42,212 |
(*) The number of shares, excluding shares authorized, have been retroactively adjusted to reflect the one-for-thirty (1-for-30) reverse stock split, which was effective on April 23, 2026. See Note 2.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.